SCHEMBL980436

SCHEMBL980436

COc1ccc(OC)c(C2=NN(C(=O)Cc3ccccc3)CC2)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.50
KDM4E B2RXH2 4/20 0.50
GAA P10253 2/20 0.50
TDP1 Q9NUW8 1/20 0.50
SMN1; SMN2 Q16637 4/20 0.49
RAB9A P51151 2/20 0.49
HPGD P15428 1/20 0.49
KMT2A Q03164 4/20 0.47
NPC1 O15118 1/20 0.47
PDE4A P27815 1/20 0.46
PDE4B Q07343 1/20 0.46
PDE4C Q08493 1/20 0.46
PDE4D Q08499 1/20 0.46
MAPT P10636 2/20 0.46
MEN1 O00255 2/20 0.44
MAOB P27338 1/20 0.44
POLB P06746 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
F10 P00742 1/20 0.44
TSHR P16473 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL981528 0.93 ALDH1A1 (0.54) ALDH1A1KDM4EGAATDP1SMN1; SMN2
SCHEMBL4628233 0.93 ALDH1A1 (0.48) ALDH1A1KDM4EGAATDP1SMN1; SMN2
SCHEMBL981809 0.91 ALDH1A1 (0.53) ALDH1A1KDM4EGAATDP1SMN1; SMN2
SCHEMBL980061 0.89 KMT2A (0.48) ALDH1A1KDM4EGAASMN1; SMN2RAB9A
SCHEMBL981598 0.88 KDM4E (0.48) ALDH1A1KDM4EGAATDP1SMN1; SMN2
SCHEMBL980134 0.87 ALDH1A1 (0.54) ALDH1A1TDP1SMN1; SMN2RAB9AHPGD
SCHEMBL982292 0.86 SIGMAR1 (0.47) ALDH1A1KDM4EGAATDP1SMN1; SMN2
SCHEMBL982146 0.84 ALDH1A1 (0.48) ALDH1A1KDM4EGAATDP1SMN1; SMN2
SCHEMBL980224 0.83 KMT2A (0.45) ALDH1A1KDM4EGAATDP1SMN1; SMN2
SCHEMBL983114 0.83 MEN1 (0.52) ALDH1A1KDM4EGAATDP1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1917248-B1 1-ACYLDIHYDROPYRAZOL DERIVATIVES MERCK PATENT GMBH (DE) 2015-08-19 EP claimed
US-7875644-B2 tyrosine kinase inhibitors, in particular Met kinase; antitumor agents;1-(Benzo-1,2,5-thiadiazol-5-ylmethylcarbonyl)-3-(2,4-dimethoxyphenyl)-4,5-dihydro-1H-pyrazole; leukemia, carcinomas MERCK PATENT GMBH (DE) 2011-01-25 US claimed
US-20080249095-A1 1-Acyldihydropyrazole Derivatives MERCK PATENT GESELLSCHAFT (DE) 2008-10-09 US claimed
EP-1917248-B1 1-ACYLDIHYDROPYRAZOL DERIVATIVES MERCK PATENT GMBH (DE) 2015-08-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080249095-A1 1-Acyldihydropyrazole Derivatives MET, FLT3, ERBB3 ALDH1A1 399/4885KDM4E 1005/4885GAA 2975/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.